61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Akebia Therapeutics Inc
Open
Sector Healthcare
2.14 0.47
Overview
Share price change
24h
Min
2.1
Max
2.17
Income | -20M |
|---|---|
Sales | 37M |
EPS | -0.1 |
Profit margin | -53.54 |
EBITDA | 1.2M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +238.21 upside |
Next Earnings | 13 Mar 2025 |
|---|
Market Cap | 10M 322M |
|---|---|
Previous open | 1.67 |
Previous close | 2.14 |
News Sentiment
By Acuity
50%
50%
160 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Akebia Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Akebia Therapeutics Inc Forecast
Price Target
By TipRanks
238.21% upside
12 Months Forecast
Average 7.17 USD 238.21%
High 10 USD
Low 4 USD
Based on 3 Wall Street analysts offering 12 month price targets forAkebia Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
160 / 393 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Akebia Therapeutics Inc
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.
